In a report released on September 7, Daina Graybosch from SVB Securities reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report), with a price target of $5.00. The company’s shares closed last Friday at $3.74.
Graybosch covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Affimed, and BioNTech SE. According to TipRanks, Graybosch has an average return of -17.1% and a 29.38% success rate on recommended stocks.
In addition to SVB Securities, Nektar Therapeutics also received a Hold from J.P. Morgan’s Jessica Fye in a report issued on September 4. However, on September 6, J.P. Morgan downgraded Nektar Therapeutics (NASDAQ: NKTR) to a Sell.
The company has a one-year high of $19.37 and a one-year low of $3.02. Currently, Nektar Therapeutics has an average volume of 2.91M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
Read More on NKTR:
- Immunovant (IMVT) Receives a Buy from SVB Securities
- Maxim Group Sticks to Its Hold Rating for Adial Pharmaceuticals (ADIL)
- Fiverr International (FVRR) Gets a Buy from JMP Securities
- Echelon Wealth Partners Sticks to Their Buy Rating for Argonaut Gold (ARNGF)
- Analysts Are Bullish on Top Consumer Goods Stocks: General Motors (GM), Mattel (MAT)